Compounds useful as chemokine receptor antagonists
申请人:Carson G. Kenneth
公开号:US20060172994A1
公开(公告)日:2006-08-03
The present invention relates to compounds useful as Chemokine Receptor antagonists. Compounds of general formula I are provided:
or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds and compositions for the inhibition of Chemokine Receptors and also for the treatment of various diseases, conditions, or disorders, including acute or chronic inflammatory disease, cancer or osteolytic bone disorders.
Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists
申请人:Carson Kenneth G.
公开号:US20110237601A1
公开(公告)日:2011-09-29
The present invention relates to compounds useful as Chemokine Receptor antagonists. Compounds of general formula I are provided:
or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds and compositions for the inhibition of Chemokine Receptors and also for the treatment of various diseases, conditions, or disorders, including acute or chronic inflammatory disease, cancer or osteolytic bone disorders.
SUBSTITUTED PIPERAZINYL-PYRROLIDINE COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS
申请人:Carson Kenneth G.
公开号:US20130123270A1
公开(公告)日:2013-05-16
The present invention relates to compounds useful as Chemokine Receptor antagonists. Compounds of general formula I are provided:
or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds and compositions for the inhibition of Chemokine Receptors and also for the treatment of various diseases, conditions, or disorders, including acute or chronic inflammatory disease, cancer or osteolytic bone disorders.
The present invention relates to compounds of Formula I
described herein and their pharmaceutically acceptable salts, and their use in medicine, in particular as Trk antagonists.